The mammalian target of rapamycin signalling network and gene regulation

Ghada A. Soliman

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Purpose of review: The mammalian target of rapamycin (mTOR) is a key integrator of signals from nutrients, energy and insulin. TOR is a protein kinase originally identified in yeast by the genetic selection of rapamycin-resistant mutants. Over the past decade mTOR research has progressed dramatically. Although mTOR is known as a controller of messenger RNA cap-dependent translation initiation, new advances implicate mTOR in the regulation of ribosomal protein gene transcription. The aim of this review is to highlight recent findings on mTOR regulatory networks, focusing on articles published from December 2003 to December 2004. Recent findings: mTOR was recently knocked out in mice; the embryonic lethal phenotype demonstrates a critical role of mTOR in early embryo development. Intriguingly, the homozygous deletion of ribosomal protein S6 kinase 1 (S6K1), an mTOR target, in mice results in hypoinsulinemia and glucose intolerance. Despite elevated levels of plasma free fatty acids, S6K1 knockout mice are protected from the metabolic syndrome, indicating a role of S6K1 in glucose homeostasis. Current research indicates that mTOR integrates input from multiple upstream pathways, including insulin, growth factors, nutrients, mitogens and energy. Furthermore, the discovery of mTOR binding partners adds to the intricacies of mTOR as a master switch in cell signaling. Summary: Rapamycin, an mTOR inhibitor, has emerged as an immunosuppressive and antiproliferative drug, and is considered a novel antitumor agent. A better understanding of mTOR signaling would enhance the clinical usefulness of rapamycin and inform consideration of mTOR as a target for the development of new therapies.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalCurrent Opinion in Lipidology
Volume16
Issue number3
DOIs
StatePublished - Jun 2005

Fingerprint

Gene Regulatory Networks
Sirolimus
Gene expression
Ribosomal Protein S6 Kinases
Nutrients
RNA Caps
Insulin
Cell signaling
Glucose
Food
Glucose Intolerance
Ribosomal Proteins
Genetic Selection
Transcription
Immunosuppressive Agents
Mitogens
Research
Nonesterified Fatty Acids

Keywords

  • 4EBP-1
  • Cell growth and proliferation
  • S6K1
  • Tuberous sclerosis complex
  • mTOR

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Genetics
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine
  • Cell Biology

Cite this

The mammalian target of rapamycin signalling network and gene regulation. / Soliman, Ghada A.

In: Current Opinion in Lipidology, Vol. 16, No. 3, 06.2005, p. 317-323.

Research output: Contribution to journalReview article

@article{ceb24afb668940a3acb507b268443a14,
title = "The mammalian target of rapamycin signalling network and gene regulation",
abstract = "Purpose of review: The mammalian target of rapamycin (mTOR) is a key integrator of signals from nutrients, energy and insulin. TOR is a protein kinase originally identified in yeast by the genetic selection of rapamycin-resistant mutants. Over the past decade mTOR research has progressed dramatically. Although mTOR is known as a controller of messenger RNA cap-dependent translation initiation, new advances implicate mTOR in the regulation of ribosomal protein gene transcription. The aim of this review is to highlight recent findings on mTOR regulatory networks, focusing on articles published from December 2003 to December 2004. Recent findings: mTOR was recently knocked out in mice; the embryonic lethal phenotype demonstrates a critical role of mTOR in early embryo development. Intriguingly, the homozygous deletion of ribosomal protein S6 kinase 1 (S6K1), an mTOR target, in mice results in hypoinsulinemia and glucose intolerance. Despite elevated levels of plasma free fatty acids, S6K1 knockout mice are protected from the metabolic syndrome, indicating a role of S6K1 in glucose homeostasis. Current research indicates that mTOR integrates input from multiple upstream pathways, including insulin, growth factors, nutrients, mitogens and energy. Furthermore, the discovery of mTOR binding partners adds to the intricacies of mTOR as a master switch in cell signaling. Summary: Rapamycin, an mTOR inhibitor, has emerged as an immunosuppressive and antiproliferative drug, and is considered a novel antitumor agent. A better understanding of mTOR signaling would enhance the clinical usefulness of rapamycin and inform consideration of mTOR as a target for the development of new therapies.",
keywords = "4EBP-1, Cell growth and proliferation, S6K1, Tuberous sclerosis complex, mTOR",
author = "Soliman, {Ghada A.}",
year = "2005",
month = "6",
doi = "10.1097/01.mol.0000169352.35642.06",
language = "English (US)",
volume = "16",
pages = "317--323",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The mammalian target of rapamycin signalling network and gene regulation

AU - Soliman, Ghada A.

PY - 2005/6

Y1 - 2005/6

N2 - Purpose of review: The mammalian target of rapamycin (mTOR) is a key integrator of signals from nutrients, energy and insulin. TOR is a protein kinase originally identified in yeast by the genetic selection of rapamycin-resistant mutants. Over the past decade mTOR research has progressed dramatically. Although mTOR is known as a controller of messenger RNA cap-dependent translation initiation, new advances implicate mTOR in the regulation of ribosomal protein gene transcription. The aim of this review is to highlight recent findings on mTOR regulatory networks, focusing on articles published from December 2003 to December 2004. Recent findings: mTOR was recently knocked out in mice; the embryonic lethal phenotype demonstrates a critical role of mTOR in early embryo development. Intriguingly, the homozygous deletion of ribosomal protein S6 kinase 1 (S6K1), an mTOR target, in mice results in hypoinsulinemia and glucose intolerance. Despite elevated levels of plasma free fatty acids, S6K1 knockout mice are protected from the metabolic syndrome, indicating a role of S6K1 in glucose homeostasis. Current research indicates that mTOR integrates input from multiple upstream pathways, including insulin, growth factors, nutrients, mitogens and energy. Furthermore, the discovery of mTOR binding partners adds to the intricacies of mTOR as a master switch in cell signaling. Summary: Rapamycin, an mTOR inhibitor, has emerged as an immunosuppressive and antiproliferative drug, and is considered a novel antitumor agent. A better understanding of mTOR signaling would enhance the clinical usefulness of rapamycin and inform consideration of mTOR as a target for the development of new therapies.

AB - Purpose of review: The mammalian target of rapamycin (mTOR) is a key integrator of signals from nutrients, energy and insulin. TOR is a protein kinase originally identified in yeast by the genetic selection of rapamycin-resistant mutants. Over the past decade mTOR research has progressed dramatically. Although mTOR is known as a controller of messenger RNA cap-dependent translation initiation, new advances implicate mTOR in the regulation of ribosomal protein gene transcription. The aim of this review is to highlight recent findings on mTOR regulatory networks, focusing on articles published from December 2003 to December 2004. Recent findings: mTOR was recently knocked out in mice; the embryonic lethal phenotype demonstrates a critical role of mTOR in early embryo development. Intriguingly, the homozygous deletion of ribosomal protein S6 kinase 1 (S6K1), an mTOR target, in mice results in hypoinsulinemia and glucose intolerance. Despite elevated levels of plasma free fatty acids, S6K1 knockout mice are protected from the metabolic syndrome, indicating a role of S6K1 in glucose homeostasis. Current research indicates that mTOR integrates input from multiple upstream pathways, including insulin, growth factors, nutrients, mitogens and energy. Furthermore, the discovery of mTOR binding partners adds to the intricacies of mTOR as a master switch in cell signaling. Summary: Rapamycin, an mTOR inhibitor, has emerged as an immunosuppressive and antiproliferative drug, and is considered a novel antitumor agent. A better understanding of mTOR signaling would enhance the clinical usefulness of rapamycin and inform consideration of mTOR as a target for the development of new therapies.

KW - 4EBP-1

KW - Cell growth and proliferation

KW - S6K1

KW - Tuberous sclerosis complex

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=20544451118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544451118&partnerID=8YFLogxK

U2 - 10.1097/01.mol.0000169352.35642.06

DO - 10.1097/01.mol.0000169352.35642.06

M3 - Review article

C2 - 15891393

AN - SCOPUS:20544451118

VL - 16

SP - 317

EP - 323

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 3

ER -